Arthritis Research & Therapy · 2023 · 25 citations · 27 references
PharmacyPharmacologyPharmacotherapyBioavailabilityDrug RepurposingHuman NutritionGoutGout PharmacotherapyMetabolic EvaluationPharmacologic Management Of GoutUrinary ExcretionAnti-inflammatory ActivityCitrate SupplementationDietary Management Of GoutSodium Bicarbonate SupplementationSodium Bicarbonate TherapyUrine AcidificationUrine Ph AbnormalitiesUrine Ph Evaluation
BACKGROUND: Low urine pH, which may be mediated by metabolic syndrome (MetS), is common in gout. Tart cherries are shown to improve MetS symptoms and possess anti-inflammatory properties. However, the efficacy of tart cherry supplements on urine pH has yet to be studied. OBJECTIVES: This study aimed to investigate the efficacy and safety of tart cherry supplementary citrate (TaCCi) mixture on urine pH, serum urate (sUA), C-reactive protein (CRP), and gout flares in gout patients initiating urate-lowering therapy (ULT), in comparison to citrate mixture and sodium bicarbonate. METHODS: A prospective, randomized (1:1:1), open-label, parallel-controlled trial was conducted among 282 men with gout and fasting urine pH ≤ 6, who were initiating ULT with febuxostat (initially 20 mg daily, escalating to 40 mg daily if serum urate ≥ 360 μmol/L). Participants were randomized to groups taking either sodium bicarbonate, citrate mixture, or TaCCi mixture. All participants were followed every 4 weeks until week 12. Urine pH and sUA were co-primary outcomes, with various biochemical and clinical secondary endpoints. RESULTS: Urine pH increased to a similar extent in all three groups. SUA levels declined in all three groups as well, with no significant differences observed between the groups. At week 12, the TaCCi mixture group exhibited a greater reduction in the urine albumin/creatinine ratio (UACR) compared to the other two groups (p < 0.05). Participants taking TaCCi mixture or citrate mixture experienced fewer gout flares than those in the sodium bicarbonate group over the study period (p < 0.05). Additionally, the TaCCi mixture group had a lower CRP level at week 12 relative to the other two groups (p < 0.01). Adverse events were similar across all three groups. CONCLUSION: The TaCCi mixture had similar efficacy and safety on urine alkalization and sUA-lowering as the citrate mixture and sodium bicarbonate in patients with gout. However, the TaCCi mixture resulted in greater improvements in UACR and CRP, which suggests that tart cherry supplements may provide additional benefits for renal protection and reduce inflammation in gout, particularly when starting ULT. TRIAL REGISTRATION: This project was registered in ChiCTR ( www.chictr.org.cn ), with the registration number: ChiCTR2100050749.
27
KDIGO 2021 Clinical Practice Guideline for the Management of Glomerular Diseases
Brad H. Rovin, Sharon G. Adler, Jonathan Barratt et al. · Kidney International · 2021 · 2.4K citations · Full text
2020 American College of Rheumatology Guideline for the Management of Gout
John FitzGerald, Nicola Dalbeth, Ted R. Mikuls et al. · Arthritis Care & Research · 2020 · 955 citations · Full text
2020 American College of Rheumatology Guideline for the Management of Gout
John FitzGerald, Nicola Dalbeth, Ted R. Mikuls et al. · Arthritis & Rheumatology · 2020 · 792 citations · Full text
Association of urinary pH with body weight in nephrolithiasis
Naim M. Maalouf, Khashayar Sakhaee, Joan H. Parks et al. · Kidney International · 2004 · 405 citations · Full text
Medicine, Nephrology, Urology +10
Type 2 Diabetes Increases the Risk for Uric Acid Stones
Michel Daudon, Olivier Traxer, Pierre Conort et al. · Journal of the American Society of Nephrology · 2006 · 336 citations
Medicine, Nephrology, Urology +16